BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9731198)

  • 1. Cellular responses in mouse leukemia L1210 cells made resistant to deoxyadenosine.
    Cory AH; Cory JG
    Biochem Biophys Res Commun; 1998 Aug; 249(3):687-91. PubMed ID: 9731198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis induced by inhibitors of nucleotide synthesis in deoxyadenosine-resistant leukemia L1210 cells that lack p53 expression.
    Cory AH; Hickerson DH; Cory JG
    Anticancer Res; 2000; 20(6B):4171-8. PubMed ID: 11205244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced roscovitine-induced apoptosis is mediated by a caspase-3-like activity in deoxyadenosine-resistant mouse leukemia L1210 cells.
    Somerville L; Cory JG
    Anticancer Res; 2000; 20(5B):3347-55. PubMed ID: 11131634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmentation of apoptosis responses in p53-deficient L1210 cells by compounds directed at blocking NFkappaB activation.
    Cory AH; Cory JG
    Anticancer Res; 2001; 21(6A):3807-11. PubMed ID: 11911251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered sensitivity of deoxyadenosine-resistant mouse leukemia L1210 cells to various kinase inhibitors.
    Somerville L; Cory JG
    Anticancer Res; 1999; 19(2A):1021-6. PubMed ID: 10368649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered steady-state levels of the messenger RNAs for c-myc and p53 in L1210 cell lines resistant to deoxyadenosine.
    Cory JG; Cory AH; Long SD; Carter GL; Johnson CE
    Cancer Res; 1992 Apr; 52(7):2000-3. PubMed ID: 1551129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased sensitivity to sodium salicylate-induced apoptosis in drug-resistant leukemia L1210 cells.
    Hall JG; Cory AH; Hickerson DH; Cory JG
    Anticancer Res; 2001; 21(1A):173-80. PubMed ID: 11299731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ionizing radiation on wild-type and mutant mouse leukemia L1210 cells.
    He AW; Cory JG
    Oncol Res; 1998; 10(9):455-64. PubMed ID: 10223621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deoxyadenosine-resistant mouse leukemia L1210 cell lines with alterations in early response genes and p53.
    Cory JG; He AW; Cory AH
    Anticancer Res; 1996; 16(6B):3483-9. PubMed ID: 9042210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered sensitivity of deoxyadenosine-resistant mouse leukemia L1210 cells to apoptosis induced by 7-hydroxystaurosporine.
    Somerville L; Cory JG
    Int J Oncol; 2000 Oct; 17(4):797-803. PubMed ID: 10995894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of doxorubicin on wild-type and deoxyadenosine-resistant mouse leukemia L1210 cells.
    He AW; Cory JG
    Int J Oncol; 1999 May; 14(5):891-5. PubMed ID: 10200338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipyridamole enhancement of toxicity to L1210 cells by deoxyadenosine and deoxycoformycin combinations in vitro.
    Kang GJ; Kimball AP
    Cancer Res; 1984 Feb; 44(2):461-6. PubMed ID: 6362851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lactacystin, a proteasome inhibitor, potentiates the apoptotic effect of parthenolide, an inhibitor of NFkappaB activation, on drug-resistant mouse leukemia L1210 cells.
    Cory AH; Cory JG
    Anticancer Res; 2002; 22(6C):3805-9. PubMed ID: 12552998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on wild type and variant mouse leukemia L1210 cells.
    Cory AH; Hertel LW; Kroin JS; Cory JG
    Oncol Res; 1993; 5(2):59-63. PubMed ID: 8364254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective resistance of L1210 cell lines to inhibitors directed at the subunits of ribonucleotide reductase.
    Carter GL; Cory JG
    Adv Enzyme Regul; 1989; 29():123-39. PubMed ID: 2699151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bis(2-hydroxybenzylidene)acetone, a potent inducer of the phase 2 response, causes apoptosis in mouse leukemia cells through a p53-independent, caspase-mediated pathway.
    Dinkova-Kostova AT; Cory AH; Bozak RE; Hicks RJ; Cory JG
    Cancer Lett; 2007 Jan; 245(1-2):341-9. PubMed ID: 16517063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of N-(phosphonacetyl)-L-aspartate and pyrazofurin depletion of pyrimidine ribonucleotide and deoxyribonucleotide pools and their relationship to nucleic acid synthesis in intact and permeabilized cells.
    Moyer JD; Smith PA; Levy EJ; Handschumacher RE
    Cancer Res; 1982 Nov; 42(11):4525-31. PubMed ID: 7127293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability.
    Huang A; Fan H; Taylor WR; Wright JA
    Cancer Res; 1997 Nov; 57(21):4876-81. PubMed ID: 9354452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockage of cyclin cdk's, PKC and phosphoinositol 3-kinase pathways leads to augmentation of apoptosis in drug-resistant leukemia cells: evidence for interactive effects of flavopiridol, LY 294002, roscovitine,wortmannin and UCN-01.
    Cory AH; Somerville L; Cory JG
    Anticancer Res; 2005; 25(1A):101-6. PubMed ID: 15816525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors.
    Cory JG; Carter GL
    Cancer Res; 1988 Feb; 48(4):839-43. PubMed ID: 3276399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.